FIA
ADMA icon

FNY Investment Advisers’s ADMA Biologics ADMA Stock Holding History

FNY Investment Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13,400
Closed -$196K – 896
2025
Q3 		$196K Buy
+13,400
New +$230K 0.06% 275
2023
Q2 		– Sell
-75
Closed – – 519
2023
Q1 		$0 Sell
75
-5,022
-99% -$17.4K ﹤0.01% 545
2022
Q4 		$19K Buy
5,097
+5,022
+6,696% +$15.5K 0.03% 254
2022
Q3 		$0 Hold
75
– – ﹤0.01% 633
2022
Q2 		$0 Hold
75
– – ﹤0.01% 683
2022
Q1 		$0 Hold
75
– – ﹤0.01% 730
2021
Q4 		$0 Hold
75
– – ﹤0.01% 536
2021
Q3 		$0 Hold
75
– – ﹤0.01% 680
2021
Q2 		$0 Hold
75
– – ﹤0.01% 762
2021
Q1 		$0 Hold
75
– – ﹤0.01% 762
2020
Q4 		$0 Hold
75
– – ﹤0.01% 754
2020
Q3 		$0 Buy
+75
New +$206 ﹤0.01% 465

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

FNY Investment Advisers's ADMA Position: Q4 2025 in Review

FNY Investment Advisers sold out of ADMA Biologics (ADMA) in Q4 2025, closing a stake of 13,400 shares — an estimated $196K sold.

FNY Investment Advisers first reported a position in ADMA in Q3 2020 and held it in 12 quarters. The position peaked at $196K in Q3 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q4 2025.

  • FNY Investment Advisers reported no remaining ADMA Biologics position as of Q4 2025 after selling out during the quarter.
  • FNY Investment Advisers sold 13,400 ADMA Biologics shares in Q4 2025, an estimated $196K.
  • FNY Investment Advisers first reported a position in ADMA Biologics in Q3 2020 and held it in 12 quarters.
  • FNY Investment Advisers's ADMA Biologics position peaked at $196K in Q3 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2025.

Based on FNY Investment Advisers's 13F filing for Q4 2025, filed 16 Jan 2026.